March 31st, 2014, Beijing, China 

Shenogen Pharma Group announces the addition of Dr. Douglas Hanahan to its Scientific Advisory Board (SAB). Dr. Douglas Hanahan is a professor of Molecular Oncology in Swiss Federal Institute of Technology in Lausanne (EPFL), Director of the Swiss Institute for Experimental Cancer Research (ISREC) and Vice Director of Swiss Cancer Center Lausanne.

“We are delighted to welcome Dr. Douglas Hanahan to our SAB, with his extensive experience in cancer research.” said Dr. Kun Meng, Chairman & CEO of Shenogen. “Dr. Hanahan is a pioneer in genetic engineering mouse model for investigating tumor formation and progression. He has not only greatly contributed to molecular genetics and cancer research in laboratories, but also organized tens of worldwide scientific communities in nearly 30 years. His article “The Hallmark of Cancer” becomes a classical for cancer research for last 20 years. We are sure that his advice will be helpful for us making better decision of development direction and future strategy.”

Dr. Hanahan regards Shenogen as to be a leading biopharma company in China with innovative technology and cancer target. He plans to work with Shenogen scientists to research and develop more efficient targeted drugs for cancer treatment. 

Dr. Hanahan is a fellow of the American Academy of Arts & Sciences, the Institution of Medicine of the US National Academies, the US National Academy of Science and the European Molecular Biology Organization (EMBO). He has been awarded many times for his contribution to cancer research, including Grand Prize for Biology from the National Cancer Association of France, Award for Cancer Research from the Fondazione San Salvatore and Lifetime Achievement Award by American Association for Cancer Research (AACR). Dr. Hanahan has authored about 150 publications, including a number of influential articles, notably one co-authored with Judah Folkman on "the angiogenic switch" that is a defining event for most cancers, and another with Bob Weinberg on "the hallmarks of cancer", which presented a conceptual organizing principle for interrelating the genetic and phenotypic complexity of tumors in diverse organs.  

Dr. Hanahan joins Drs. V. Craig Jordan, Robert N. Eisenman and Changxiao Liu who are currently members of Shenogen’s Scientific Advisory Board. 

About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.